ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGC vs OBIO // GROSS PROFIT MARGIN

Canopy Growth Corporation (NASDAQ) VS. Orchestra BioMed Holdings Inc. (NASDAQ) • 15-METRIC TALLY: CGC 0 — OBIO 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGC VS. OBIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGC OBIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -13.51% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 OBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.6 57.3 -23.70 OBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $285.6M $366.0M -$80.5M OBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGC REV OBIO REV CGC GROSS % OBIO GROSS % CGC FCF OBIO FCF
FY 2025 $0 $33.5M — 98.0% — -$49.5M
FY 2024 $0 $2.6M — 92.3% — -$50.8M
FY 2023 $0 $2.8M — — — -$46.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGC // BETA —
OBIO // BETA —